AD/PD 2024 | Evolving use of tau-specific fluid biomarkers for Alzheimer’s disease

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, briefly comments on the evolving use of novel tau-specific biomarkers. Tau-specific biomarkers are of great importance for drug development and clinical diagnosis given the strong correlation between clinical symptoms and tau burden. Additionally, the use of intermediate-tau trial inclusion designs is rising, with evidence suggesting these patients may benefit the most from anti-amyloid therapy. Dr Lukasewicz Ferreira highlights that the cerebrospinal fluid biomarker microtubule-binding region of tau containing residue 243 (MTBR-tau243) has shown promise and must be further investigated. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.